Scissortail Wealth Management LLC Increases Position in Johnson & Johnson (NYSE:JNJ)

Scissortail Wealth Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5,251.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 21,726 shares of the company's stock after purchasing an additional 21,320 shares during the period. Scissortail Wealth Management LLC's holdings in Johnson & Johnson were worth $3,142,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. R.H. Investment Group LLC bought a new position in Johnson & Johnson in the 4th quarter valued at approximately $3,623,000. Founders Grove Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $972,000. Nabity Jensen Investment Management Inc lifted its holdings in shares of Johnson & Johnson by 4.2% during the fourth quarter. Nabity Jensen Investment Management Inc now owns 4,555 shares of the company's stock valued at $659,000 after purchasing an additional 182 shares in the last quarter. Apella Capital LLC lifted its holdings in shares of Johnson & Johnson by 1.5% during the fourth quarter. Apella Capital LLC now owns 24,335 shares of the company's stock valued at $3,519,000 after purchasing an additional 348 shares in the last quarter. Finally, Wolff Wiese Magana LLC boosted its position in shares of Johnson & Johnson by 2.5% during the fourth quarter. Wolff Wiese Magana LLC now owns 3,832 shares of the company's stock valued at $554,000 after buying an additional 92 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on JNJ shares. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Bank of America decreased their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $169.00 to $153.00 in a research report on Tuesday. Finally, Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Up 1.2%

NYSE JNJ opened at $151.37 on Friday. The stock's 50-day moving average price is $156.27 and its 200-day moving average price is $153.94. The company has a market capitalization of $364.20 billion, a P/E ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.